



Noxopharm Limited ([ASX:NOX](#)) | ASX Announcement | 31 May 2021

Results of Extraordinary General Meeting

Sydney 31 May 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announces the results of today's Extraordinary General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

All resolutions were passed and decided by way of a poll.

-ENDS-

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au



Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Disclosure of Proxy Votes

NOXOPHARM LIMITED

Extraordinary General Meeting

Monday, 31 May 2021



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

| Resolution | Decided by Show of Hands (S) or Poll (P) | Total Number of Proxy Votes exercisable by proxies validly appointed | Proxy Votes | | | | Poll Results (if applicable) | | |
|---|--|--|----------------------|------------------|-----------|--------------------|------------------------------|------------------|-----------|
| | | | FOR | AGAINST | ABSTAIN | PROXY'S DISCRETION | FOR | AGAINST | ABSTAIN |
| 1 Subsequent approval of prior issue of Shares | P | 51,643,514 | 50,167,270 97.14% | 375,257 0.73% | 76,332 | 1,100,987 2.13% | 54,566,719 99.32% | 375,257 0.68% | 82,044 |
| 2 Approval of Issue of Shares to related party of Frederik Bart, Director related to Amended Loan Agreement | P | 59,513,322 | 58,170,053 97.74% | 241,425 0.41% | 76,332 | 1,101,844 1.85% | 60,111,897 99.60% | 241,425 0.40% | 2,620,506 |
| 3 Approval of Issue of Shares to Link related to Amended Loan Agreement | P | 54,072,098 | 52,712,954 97.49% | 257,300 0.48% | 76,332 | 1,101,844 2.04% | 57,193,260 99.55% | 257,300 0.45% | 82,044 |
| 4 Approval of Issue of Shares to Goodridge Investments related to Amended Loan Agreement | P | 58,145,951 | 56,736,807 97.58% | 307,300 0.53% | 1,443,703 | 1,101,844 1.89% | 61,217,113 99.50% | 307,300 0.50% | 1,449,415 |
| 5 Approval of Issue of Incentive Options to Boris Patkin, Director | P | 59,492,579 | 57,954,827 97.42% | 435,908 0.73% | 97,075 | 1,101,844 1.85% | 61,765,133 99.30% | 435,908 0.70% | 772,787 |

